Microprotein Dysregulation in the Serum of Patients with Atrial Fibrillation-Reference-Cited by-同舟云学术

Microprotein Dysregulation in the Serum of Patients with Atrial Fibrillation

Published:2023-03-16 Issue:4 Volume:22 Page:1172-1180
ISSN:1535-3893
Container-title:Journal of Proteome Research
language:en
Short-container-title:J. Proteome Res.

Author:

Zhang Zheng¹^ORCID,Tian Tao²,Pan Ni¹,Wang Yi¹,Peng Mingbo¹,Zhao Xinbo²,Pan Zhenwei²,Wan Cuihong¹^ORCID

Affiliation:

1. School of Life Sciences and Hubei Key Laboratory of Genetic Regulation and Integrative Biology, Central China Normal University, Wuhan, Hubei 430079, People’s Republic of China

2. Department of Pharmacology, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education; State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Harbin Medical University, Harbin, Heilongjiang 150081, People’s Republic of China

Funder

Central China Normal University

National Natural Science Foundation of China

Publisher

American Chemical Society (ACS)

Subject

General Chemistry,Biochemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jproteome.2c00622

Reference43 articles.

1. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)

2. Atrial fibrillation and long-term prognosis in patients hospitalized for heart failure: results from heart failure survey in Israel (HFSIS)

3. Independent Risk Factors for Atrial Fibrillation in a Population-Based Cohort

4. Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options--a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference

5. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary